Harvard Bioscience (Harvard Bioscience) Cash And Cash Equivalents

: $4.3 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Harvard Bioscience's quarterly cash and cash equivalents increased from Jun. 2023 ($4.32 Mil) to Sep. 2023 ($5.34 Mil) but then stayed the same from Sep. 2023 ($5.34 Mil) to Dec. 2023 ($4.28 Mil).

Harvard Bioscience's annual cash and cash equivalents declined from Dec. 2021 ($7.82 Mil) to Dec. 2022 ($4.51 Mil) and declined from Dec. 2022 ($4.51 Mil) to Dec. 2023 ($4.28 Mil).

Harvard Bioscience Cash And Cash Equivalents Historical Data

The historical data trend for Harvard Bioscience's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

8.34

8.32

7.82

4.51

4.28

Harvard Bioscience Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents																4.51	3.79	4.32	5.34	4.28

Harvard Bioscience Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Harvard Bioscience (NAS:HBIO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Harvard Bioscience Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Harvard Bioscience's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Harvard Bioscience (Harvard Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Harvard Bioscience Inc (NAS:HBIO) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

HBI:Germany

Address

84 October Hill Road, Holliston, MA, USA, 01746

Website

https://www.harvardbioscience.com

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.

Executives

James W Green	director, officer: Chief Executive Officer	12525 CHADRON AVENUE, HAWTHORNE CA 90250
Alan I Edrick	director	20200 SUNBURST STREET, CHATSWORTH CA 91311
Jennifer Cote	officer: Interim CFO	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Bertrand Loy	director	C/O ENTEGRIS, INC., 129 CONCORD RD, BILLERICA MA 01821
Thomas W Loewald	director	81 WYMAN STREET, WALTHAM MA 02451
John F Kennedy	director	C/O NET PERCEPTIONS INC, 7700 FRANCE AVE. SOUTH, EDINA MN 55435
Katherine A. Eade	director	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Susan M. Steele	director	C/O HILL INTERNATIONAL, INC., 2005 MARKET ST., 17TH FLOOR, PHILADELPHIA PA 19103
Kenneth Fletcher Olson	officer: Chief Operating Officer	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Michael A. Rossi	officer: Chief Financial Officer	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Yash Singh	officer: Executive Vice President	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Jeffrey Duchemin	officer: Chief Executive Officer	14 EASTLAND TERRACE, HAVERHILL MA 01830
Kamalam Unninayar	officer: Chief Financial Officer	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Robert E. Gagnon	officer: Chief Financial Officer	C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
George Uveges	director	C/O MFIC CORPORATION, 30 OSSIPEE ROAD, NEWTON MA 02464